FDA
-
-
-
-
-
-
-
Innovation Pharma Completes Enrollment in Phase 2 Clinical Trial for COVID-19
-
-
-
-
-
-
-
Innovation Pharma’s COVID-19 Drug Candidate Brilacidin Ranked in Top Three Percent of Compounds Predicted to Be Most Effective Against SARS-CoV-2
-
-
-
-
-
-
-
Innovation Pharmaceuticals COVID-19 Clinical Trial to Support Additional Development of Brilacidin as a “Pan-Coronavirus” Therapeutic
-
-
-
-
-
-
-
Dr. William F. DeGrado, a Discoverer of Brilacidin, Joins Innovation Pharmaceuticals as Scientific Advisor
-
-
-
-
-
-
-
Innovation Pharmaceuticals (IPIX) Reports Brilacidin Inhibits SARS-CoV-2 (COVID-19) by 97 Percent in a Human Lung Cell Line
-
-
-
-
-
-
-
Inhibitory Effect of Innovation Pharmaceuticals’ Brilacidin on SARS-CoV-2 (COVID-19) in Primary Human Immune Cells to be Studied at Leading Public Health Research Institute
-
-
-
-
-
-
-
Innovation Pharmaceuticals Brilacidin Received by U.S. Regional Biocontainment Laboratory; Testing Against Coronavirus (COVID-19)
-
324,764 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

